依达拉奉治疗糖尿病性脑梗死43例临床观察

Clinic observation on edaravone in the treatment of acute cerebral infarction patients with diabetes mellitus

目的观察依达拉奉配合治疗糖尿病性脑梗死患者的临床疗效。方法糖尿病性急性脑梗死患者共43例,随机分为治疗组和对照组,治疗组给予依达拉奉30mg溶于0.9%生理盐水100ml中静滴,每日2次,14天为一疗程。对照组采用常规治疗药物川芎注射液100ml静滴,每日2次,14天为一疗程。4周后以神经功能缺损程度治疗百分率评定疗效。结果治疗组痊愈8例,显著进步15例,进步9例,无效11例;对照组痊愈4例,显著进步8例,进步11例,无效16例。治疗组疗效优于对照组(P=0.0489)。结论依达拉奉治疗糖尿病性脑梗死效果优于常规药物治疗。

Objective To observe clinical efficacy of Edaravone on the treatment of acute cerebral infarction patients with diabetes mellitus. Methods Acute cerebral infarction patients with diabetes mellitus were randomly divided into treatment group and control group. The edaravone injection 30 mg was dissolved in sodium chloride injection 100 ml for treatment group pa- tients, twice a day for 10-14 d. The control group were given Ligustrazine injection 100 ml, twice a day for 10-14 d. All pa- tients were scored by clinic effects evaluation standard four weeks later. Results In treatment and control groups, complete re- covery was eight and four, significant progress was 15 and eight, progress was nine and 11, no effect was 11 and 16. There were significant differences between treatment group and control group （P：0. 0489）. Conclusion Compared with the standard treatment, Edaravone can improve effectively the nerve function impairment of acute cerebral infarction patients with diabetes mellitus.